Apeiron's to seek more neuroblastoma partners after Paladin gets in first
This article was originally published in Scrip
Executive Summary
Apeiron Biologics has licensed, APN311, its antibody-based immunotherapy for neuroblastoma, to Canadian speciality pharmaceutical company, Paladin Labs, which now has exclusive rights to market and sell the orphan candidate in Canada and sub-Saharan Africa (including South Africa). No further details or financial terms of the transaction were disclosed.